Page 41 - Hormel Institute Annual Report 2021-22

Epigenetic regulation of hypoxia signaling in glioblastoma cells.
We found that disruption of RBBP4/p300 complex impairs the ability of cells to induce HIF1-A in response to hypoxia, suggesting that this chromatin complex may be important for hypoxia signaling in cancer cells, including GBM. This project will mechanistically link this complex with hypoxia and angiogenesis. The overar- ching goal is to test whether targeting this complex could sensitize GBM and other cancer cells to HIF1-A inhibitors.
| 41
Recent Publications:
• Mladek, A. C., Yan, H., Tian, S., Decker, P. A., Burgenske, D. M., Bakken, K., Hu, Z., He, L., Connors, M. A., Carlson, B. L., Wilson, J., Bommi-Reddy, A., Conery, A., Eckel-Passow, J. E., Sarkaria, J. N., & Kitange, G. J. (2022). RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma. Neuro Oncol, 24(8), 1261-1272.
• Daniel, P., Meehan, B., Sabri, S., Jamali, F., Sarkaria, J. N., Choi, D., Garnier, D., Kitange, G., Glennon, K. I., Paccard, A., Karamchandani, J., Riazalhosseini, Y., Rak, J., & Abdulkarim, B. (2022). Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma. Neurooncol Adv, 4(1), vdac076.
• Burgenske, D. M., Talele, S., Pokorny, J. L., Mladek, A. C., Bakken, K. K., Carlson, B. L., Schroeder, M. A., He, L., Hu, Z., Gampa, G., Kosel, M. L., Decker, P. A., Kitange, G. J., Schmitt-Hoffmann, A., Bachmann, F., Vaubel, R. A., Eckel-Passow, J. E., Giannini, C., McSheehy, P., Lane, H. A., Elmquist, W. F., & Sarkaria, J. N. (2022). Preclinical modeling in glioblastoma patient- derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules. Neuro Oncol, 24(3), 384-395.